美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

避孕概念

2,138.56

+3.690.17%

漲家數：3

跌家數：2

平家數：- -

市盈率：- -

高：2,184.15

開：2,150.83

低：2,129.92

收：2,134.87

成交量：1,211.75萬

成交額：1.64億

市值：343.54億

流通市值：336.53億

資料載入中...

總覽新聞資訊

Femasys Inc 修訂案將於2025年12月31日生效：移除票據與認股權證中的股份合併事件調整條款

Veru Inc.啓動恩博沙姆與司美格魯肽聯合療法用於高質量減重的2B期平台臨床試驗，首位患者入組

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/BK4584/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"避孕概念","latestPrice":2138.5625,"timestamp":1774295999999,"preClose":2134.8713,"halted":0,"volume":12117452,"delay":0,"changeRate":0.001729,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":3.691162,"latestTime":"03-23 16:00:00 EDT","open":2150.8262,"high":2184.1477,"low":2129.9165,"amount":164173756.008417,"amplitude":0.025403,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774339200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.447776,"peRate":25.857654,"turnoverRate":0.007975,"increases":3,"decrements":2,"flats":0,"marketCap":34353940654,"floatMarketCap":33652961166},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2184.1477,"amplitude":0.025403,"preClose":2134.8713,"low":2129.9165,"pbRate":"4.447776","latestPrice":2138.5625,"volume":12117452,"delay":0,"open":2150.8262,"prevYearClose":2379.9924,"prevWeekClose":2134.8713,"prevMonthClose":2521.1123,"prevQuarterClose":2379.9924,"fiveDayClose":2196.147,"twentyDayClose":2570.1104,"sixtyDayClose":2409.9392,"secType":"PLATE","market":"US","turnoverRate":0.007975,"peRate":25.857654,"marketCap":34353940654,"floatMarketCap":33652961166,"timestamp":1774295999999,"nameCN":"避孕概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1141975391","title":"Femasys Inc 修訂案將於2025年12月31日生效：移除票據與認股權證中的股份合併事件調整條款","url":"https://stock-news.laohu8.com/highlight/detail?id=1141975391","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141975391?lang=zh_tw&edition=fundamental","pubTime":"2026-03-21 05:19","pubTimestamp":1774041553,"startTime":"0","endTime":"0","summary":"根据向美国证券交易委员会提交的最新文件，Femasys Inc 已通过一项修订案，该修订案将自2025年12月31日起正式生效。此次修订的核心内容是，从公司发行的票据和认股权证的相关条款中，移除了针对股份合并事件的调整机制。这一变动意味着，自生效日起，若公司进行股份合并，将不再触发对上述票据和认股权证的行权价格或转换比率等条款的自动调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4584","BK4082","FEMY"],"gpt_icon":0},{"id":"1168049288","title":"Veru Inc.啓動恩博沙姆與司美格魯肽聯合療法用於高質量減重的2B期平台臨床試驗，首位患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1168049288","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168049288?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 20:36","pubTimestamp":1773059779,"startTime":"0","endTime":"0","summary":"Veru Inc.宣布，其用于实现高质量减重的恩博沙姆（enobosarm）与司美格鲁肽（semaglutide）联合疗法的2B期平台临床试验已完成首位患者入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4557","BK4584","BK4183","VERU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}